NCT04040699View on ClinicalTrials.gov

KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 26, 2019

Primary Completion Date

September 22, 2022

Study Completion Date

December 1, 2023

Conditions
HER2 Positive Solid Tumor
Interventions
BIOLOGICAL

KN026 combined with KN046

KN026 and KN046 are given at 20mg/Kg and 3mg/Kg intravenously on day 1of each 2 weeks cycle at the beginning respectively.The dosage will be escalated if adverse events are tolerated according to the scheme.

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

All Listed Sponsors
collaborator

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

INDUSTRY

lead

Peking University

OTHER

NCT04040699 - KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor | Biotech Hunter | Biotech Hunter